Skip to main content
Premium Trial:

Request an Annual Quote

Caprion of Montreal Raises $4.1M for Proteomics Efforts

NEW YORK, March 13 – Canadian proteomics company Caprion Pharmaceuticals said Tuesday it had raised C$6.2 million ($4.1 million) in a secondary round of private financing managed by Yorkton Securities and led by Ventures West and Fidelity Management & Research.

Caprion of Montreal has raised a total of C$58.1 million to date, not including a C$11.6 million investment from Micromass for the application of Micromass' mass spectrometry technologies to Caprion's proteomics efforts.

“Caprion now has in excess of C$70 million in cash to meet the significant challenges we have set out for ourselves, and to compete in the emerging field of proteomics on a global scale," Lloyd Segal, Caprion CEO, said in a statement.

Caprion Pharmaceuticals has developed proprietary processes to determine cell-mapping patterns in order to better understand the role of proteins in disease.

Caprion’s cell mapping technology reveals how proteins work at the level of single organelles, including spatial and 3-D orientation information, an approach the company has said differs from that of most proteomics competitors, who work at the tissue level.  

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.